Carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals Celecoxib is a non steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) Rheumatoid Arthritis (RA) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older Ankylosing Spondylitis (AS) Acute Pain (AP) Primary Dysmenorrhea (PD) 1.1 Osteoarthritis (OA) Celecoxib is indicated for relief of the signs and symptoms of OA 1.2 Rheumatoid Arthritis (RA) Celecoxib is indicated for relief of the signs and symptoms of RA 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 21, 2015 | Original application | Approved | None posted |
| Jul 17, 2026 | Supplement 25Labeling · Standard review | Approved | None posted |
| Jul 16, 2024 | Supplement 16Labeling · Standard review | Approved | None posted |
| Sep 18, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 18, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 16, 2016 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 21, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters